{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:33:37Z","timestamp":1790519617747,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["73111208 - SFB 829"],"award-info":[{"award-number":["73111208 - SFB 829"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MU3629\/2-1"],"award-info":[{"award-number":["MU3629\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41375-020-0989-4","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T14:18:44Z","timestamp":1595254724000},"page":"887-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2659-6776","authenticated-orcid":false,"given":"Kira","family":"Allmeroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kroef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Miethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-3349","authenticated-orcid":false,"given":"Martin S.","family":"Denzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"989_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","volume":"7","author":"T Hideshima","year":"2007","unstructured":"Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585\u201398.","journal-title":"Nat Rev Cancer"},{"key":"989_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867\u201374.","journal-title":"Mayo Clin Proc"},{"key":"989_CR3","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27:3518\u201325.","journal-title":"J Clin Oncol"},{"key":"989_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18\u201335.","journal-title":"Drug Resist Updat"},{"key":"989_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","volume":"11","author":"DJ McConkey","year":"2008","unstructured":"McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11:164\u201379.","journal-title":"Drug Resist Updat"},{"key":"989_CR6","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14:1649\u201357.","journal-title":"Clin Cancer Res"},{"key":"989_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","volume":"10","author":"M Unno","year":"2002","unstructured":"Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, et al. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure. 2002;10:609\u201318.","journal-title":"Structure."},{"key":"989_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","volume":"33","author":"S Barrio","year":"2019","unstructured":"Barrio S, Stuhmer T, Da-Via M, Barrio-Garcia C, Lehners N, Besse A, et al. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia. 2019;33:447\u201356.","journal-title":"Leukemia"},{"key":"989_CR9","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281\u201390.","journal-title":"Blood."},{"key":"989_CR10","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17:5311\u201321.","journal-title":"Clin Cancer Res"},{"key":"989_CR11","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1021\/jm801329v","volume":"52","author":"HJ Zhou","year":"2009","unstructured":"Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem. 2009;52:3028\u201338.","journal-title":"J Med Chem"},{"key":"989_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S Lu","year":"2013","unstructured":"Lu S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013;1:13.","journal-title":"Biomark Res."},{"key":"989_CR13","doi-asserted-by":"publisher","first-page":"9838","DOI":"10.18632\/oncotarget.24305","volume":"9","author":"M Horn","year":"2018","unstructured":"Horn M, Kroef V, Allmeroth K, Schuller N, Miethe S, Peifer M, et al. Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells. Oncotarget. 2018;9:9838\u201351.","journal-title":"Oncotarget."},{"key":"989_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.aaf8993","volume":"353","author":"J Schrader","year":"2016","unstructured":"Schrader J, Henneberg F, Mata RA, Tittmann K, Schneider TR, Stark H, et al. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science. 2016;353:594\u20138.","journal-title":"Science."},{"key":"989_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.str.2014.11.017","volume":"23","author":"W Harshbarger","year":"2015","unstructured":"Harshbarger W, Miller C, Diedrich C, Sacchettini J. Crystal structure of the human 20S proteasome in complex with carfilzomib. Structure. 2015;23:418\u201324.","journal-title":"Structure."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0989-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:41:44Z","timestamp":1684604504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0989-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0989-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"18 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MH and MSD are shareholders in ACUS Laboratories GmbH, which uses genetic screens for target deconvolution. The other authors declare no potential conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}